Blue Lotus Non US Internet research, Blue Lotus Research Institute

Ying Pan

Blue Lotus Non US Internet research

China growth and global non-US Internet equities

Blue Lotus Research Institute

Blue Lotus Research is a Hong Kong Type 4 Licensed investment advisory firm focusing on Chinese growth equities and global non-US Internet equities

Thematic (Sector/Industry)

<ul>
<li>BABA US: Alibaba’s Qwen Team to Launch AGI-like Deep Research Functionality for Free User Access(+)</li>
<li>BABA US: Ele.me's Retail Digital System Integrated into Taobao Instashopping (+)</li>
<li>JD US/3690 HK: JD, Meituan, Ele.me Summoned by Government (///)</li>
</ul>


BABA US: Alibaba’s Qwen Team to Launch AGI-like Deep Research Functionality for Free User Access(+)
BABA US: Ele.me's Retail Digital System Integrated into Taobao Instashopping (+)
JD US/3690 HK: JD, Meituan, Ele.me Summoned by Government (///)


[Blue Lotus Daily-TMT Update]:BABA US/JD US/3690 HK/PDD US/Red Note/BILI US/1810 HK

Head of Research, IPOs & Placements, Aequitas Research

Sumeet Singh

Head of Research, IPOs & Placements

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

Jiangsu Hengrui Medicine / Equity Capital Markets

<ul>
<li>
<a href="https://www.smartkarma.com/entities/jiangsu-hengrui-medicine-co-ltd" target="_blank" data-smartkarma-citation="entities:14128:1" rel="noopener">Jiangsu Hengrui Medicine (600276 CH)</a>, a China-based pharmaceutical company, aims to raise around US$1.3bn in its H-share listing.</li>
<li>JHP Has been ranked as one of the global Top 50 pharmaceutical companies by Pharm Exec for six consecutive years since 2019.</li>
<li>We have looked at the company’s past performance and other deal dynamics in our previous note. In this note, we talk about the IPO pricing.</li>
</ul>



Jiangsu Hengrui Medicine (600276 CH), a China-based pharmaceutical company, aims to raise around US$1.3bn in its H-share listing.
JHP Has been ranked as one of the global Top 50 pharmaceutical companies by Pharm Exec for six consecutive years since 2019.
We have looked at the company’s past performance and other deal dynamics in our previous note. In this note, we talk about the IPO pricing.


Jiangsu Hengrui Pharma A/H Listing - Low-End Is Probably Close to Fair Value

Chief Executive Officer, Emmer Capital Partners Limited

Manishi Raychaudhuri

Chief Executive Officer

Emmer Capital Partners Limited

Emmer Capital Partners is an Asia Pacific focused financial advisory firm engaging in strategic financial asset allocation advice, bespoke thematic research and advising early-stage companies and connecting them to investors. Emmer Capital provides macro-economic and multi-asset investment strategy inputs to institutions, family offices, private wealth managers, private equity, and corporate boards directly and through independent research platforms. Emmer Capital also advises a wide range of startup companies on fund raising and business strategy. Emmer Capital's active engagement with the print and electronic media reaches a broad spectrum of investors across the globe.

Cross Asset Strategy

<ul>
<li>We launch the Emmer Capital Asia ex Japan Equity Model Portfolio. We shall measure the absolute and relative performance (vi-a-vis MSCI Asia-ex-Japan Index) of the portfolio and rebalance it monthly.</li>
<li>Our sector and market choices are governed by macro-economic and policy considerations. Asian consumption support, inflation divergence strengthening Asian currencies and market leading domestic exposures are some of the themes.</li>
<li>We are overweight HK/China, India, Korea; underweight Taiwan, ASEAN. We like consumer discretionary, communication services and technology, despite the latter's global footprint. We prefer high ROEs and dividend yields.</li>
</ul>


We launch the Emmer Capital Asia ex Japan Equity Model Portfolio. We shall measure the absolute and relative performance (vi-a-vis MSCI Asia-ex-Japan Index) of the portfolio and rebalance it monthly.
Our sector and market choices are governed by macro-economic and policy considerations. Asian consumption support, inflation divergence strengthening Asian currencies and market leading domestic exposures are some of the themes.
We are overweight HK/China, India, Korea; underweight Taiwan, ASEAN. We like consumer discretionary, communication services and technology, despite the latter's global footprint. We prefer high ROEs and dividend yields.


Asian Equities: Launching Our Asia Ex Japan Model Portfolio

Pan-Asia Index Rebalances/ Events/ Delta One, Periscope Analytics

Brian Freitas

Pan-Asia Index Rebalances/ Events/ Delta One

Periscope Analytics

Periscope Analytics focuses on event-driven trades across Asia Pacific and provides comprehensive, timely and systematic coverage of index changes to major Asia Pacific indices in a structured manner.

The analysis includes forecasted inclusions and exclusions to all major Asian indices that have significant amount of tracking assets, including estimates of passive buy/sell flow on the stocks. The service also provides commentary and impact of market consultations, ground rule changes, and other events (IPOs, spin-offs, M&A) that could lead to index changes and passive flow.

Periscope Analytics works with multi-strategy hedge funds, proprietary trading firms, stat arb trading groups and long-only investors that invest and trade in the Asia Pacific region with the data being used to trade index rebalances, avoid pre-positioning and passive flow, and to time entry into and exit from stocks.

Event-Driven Trades Across Asia Pacific

Index Rebalance

<ul>
<li>Post market close on Friday, Hang Seng Indexes will announce the changes for the <a href="https://www.smartkarma.com/entities/hong-kong-hang-seng-index" target="_blank" data-smartkarma-citation="entities:22899:1" rel="noopener">Hang Seng Index (HSI INDEX)</a> that will be implemented at the close on 6 June.</li>
<li>With no constituent changes, one-way turnover will be 1.9% with 3 stocks being capped and FAF changes for a few stocks due to a methodology change for Secondary Listings. </li>
<li>We highlight 7 stocks that have a higher probability of being added to the index. Everything depends on the index committee, and we would not be surprised by zero changes.</li>
</ul>


Post market close on Friday, Hang Seng Indexes will announce the changes for the Hang Seng Index (HSI INDEX) that will be implemented at the close on 6 June.
With no constituent changes, one-way turnover will be 1.9% with 3 stocks being capped and FAF changes for a few stocks due to a methodology change for Secondary Listings. 
We highlight 7 stocks that have a higher probability of being added to the index. Everything depends on the index committee, and we would not be surprised by zero changes.


Hang Seng Index (HSI) Rebalance Preview: Inclusion Candidates for June25

<ul>
<li>JD US/3690 HK:Both JD and Metiuan Raise Standards for Premium Food Delivery (+)</li>
<li>700 HK/1024 HK: Tencent Releases Multimodal Video Generation AI Model Hunyuan Custom (+/-)</li>
<li>BILI US: Bilibili Launches New AI Advertising Tool “Insight Agent” (+)</li>
</ul>


JD US/3690 HK:Both JD and Metiuan Raise Standards for Premium Food Delivery (+)
700 HK/1024 HK: Tencent Releases Multimodal Video Generation AI Model Hunyuan Custom (+/-)
BILI US: Bilibili Launches New AI Advertising Tool “Insight Agent” (+)


[Blue Lotus Daily-TMT Update]:JD US/3690 HK/700 HK/1024 HK/BILI US/BIDU US/BABA US

China

Alibaba Group Holding Limited provides online sales services. The Company provides internet infrastructure, electronic commerce, online financial, and internet content services through its subsidiaries. Alibaba Group Holding offers its products and services worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Alibaba (BABA US)

[Blue Lotus Daily-TMT Update]:BABA US/JD US/3690 HK/PDD US/Red Note/BILI US/1810 HK

Alibaba's Qwen Team to offer AGI-like deep research for free, Ele.me's retail system integrated into Taobao Instashopping, JD, Meituan, Ele.me...

Blue Lotus Research Institute

Jiangsu Hengrui Pharma A/H Listing - Low-End Is Probably Close to Fair Value

Jiangsu Hengrui Medicine (600276 CH), a China-based pharmaceutical company, aims to raise around US$1.3bn in its H-share listing. In this note, we...

Sumeet Singh

Asian Equities: Launching Our Asia Ex Japan Model Portfolio

Emmer Capital's Asia ex JP Equity Model Portfolio is Overwt on HK/CN, India, Korea & underwt Taiwan, ASEAN. We like consumer discretionary, comm...

Manishi Raychaudhuri

Hang Seng Index (HSI) Rebalance Preview: Inclusion Candidates for June25

We highlight 7 potential inclusions for the HSI in June, though the index committee could make no changes as we have seen in the past. Pop Mart...

Brian Freitas

[Blue Lotus Daily-TMT Update]:JD US/3690 HK/700 HK/1024 HK/BILI US/BIDU US/BABA US

JD and Meituan raise standards for premium food delivery, Tencent releases new AI model, Bilibili launches AI advertising tool.

Blue Lotus Research Institute

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

[Blue Lotus Daily-TMT Update]:BABA US/JD US/3690 HK/PDD US/Red Note/BILI US/1810 HK

​Alibaba's Qwen Team to offer AGI-like deep research for free, Ele.me's retail system integrated into Taobao Instashopping, JD, Meituan, Ele.me...

Blue Lotus Research Institute

Jiangsu Hengrui Pharma A/H Listing - Low-End Is Probably Close to Fair Value

Jiangsu Hengrui Medicine (600276 CH), a China-based pharmaceutical company, aims to raise around US$1.3bn in its H-share listing. In this note, we...

Sumeet Singh

Asian Equities: Launching Our Asia Ex Japan Model Portfolio

Emmer Capital's Asia ex JP Equity Model Portfolio is Overwt on HK/CN, India, Korea & underwt Taiwan, ASEAN. We like consumer discretionary, comm...

Manishi Raychaudhuri

Hang Seng Index (HSI) Rebalance Preview: Inclusion Candidates for June25

We highlight 7 potential inclusions for the HSI in June, though the index committee could make no changes as we have seen in the past. Pop Mart...

Brian Freitas

[Blue Lotus Daily-TMT Update]:JD US/3690 HK/700 HK/1024 HK/BILI US/BIDU US/BABA US

​JD and Meituan raise standards for premium food delivery, Tencent releases new AI model, Bilibili launches AI advertising tool.

Blue Lotus Research Institute

Alibaba's Qwen Team to offer AGI-like deep research for free, Ele.me's retail system integrated into Taobao Instashopping, JD, Meituan, Ele.me...

JD and Meituan raise standards for premium food delivery, Tencent releases new AI model, Bilibili launches AI advertising tool.